01—Abstract
Summary
Summary of the 10-K filed December 27, 1994. Cited figures are marked; the original filing is the authoritative source.
Becton, Dickinson and Company (BDX) closed fiscal 1994 (year ended September 30, 1994) with a strong recovery in earnings and cash generation.
Revenues rose 4% to $2.56 billiona (5% excluding unfavorable currency translation), and operating income climbed 20% to $325 million. Net income was $227 million, or $3.05 per share, versus $72 million ($0.88 per share) in 1993, which had been depressed by a $141 million after-tax cumulative effect of accounting changes. Excluding special charges and currency effects, income growth was driven by gross margin expansion (45.3% vs. 44.5%), tighter selling and administrative spending (25.8% of revenue vs. 26.8%), and benefits from U.S. medical plan changes.
The Medical Supplies and Devices segment was the primary growth engine, with operating income up 20% on strong safety syringe, insulin syringe, and prefillable syringe sales. The Diagnostic Systems segment was weaker. Its operating income was flat at $111 millionb, held back by cost-containment pressure on microbiology testing in the U.S. and Europe, competition and tight research budgets hurting FACS cellular analysis sales, and a fourth-quarter $30 million special charge tied to exiting thyroid, pregnancy, fertility, and anemia testing lines.
Management is refocusing that segment around DNA probes and clinical cellular analysis. Europe's government cost containment also weighed on instrumented systems sales. From a balance sheet and capital allocation standpoint, operating cash flow rose to $480 millionc from $320 million, while capital expenditures fell to $123 million.
The company repurchased 5.4 million shares for $210 milliond and reduced total debt by $45 million, bringing debt-to-capitalization down to 36.1%. Management signaled intent to deploy excess cash toward acquisitions and further buybacks, with 9.9 million shares still authorized, and expects a higher effective tax rate in 1995 as Puerto Rico tax benefits decline.
02—Key points
Key Highlights
- Revenue grew 4% to $2.56 billion (5% ex-currency), with both segments contributing growth across U.S. and international markets.
- Operating income rose 20% to $325 million; gross margin improved to 45.3% from 44.5% on product mix and manufacturing cost reductions.
- Net income of $227 million ($3.05/share) rebounded sharply from $72 million in 1993, which included a $141 million accounting-change charge.
- Medical Supplies and Devices operating income rose 20% to $274 million, led by safety hypodermic products, insulin syringes, and prefillable syringes.
- Diagnostic Systems operating income was flat at $111 million; a $30 million Q4 special charge accompanied exits from thyroid, pregnancy, fertility, and anemia testing lines.
- Operating cash flow nearly doubled to $480 million, funding $123 million in capex, $210 million in share repurchases, and a $45 million debt reduction.
- Debt-to-capitalization fell to 36.1% from 37.8%, and book value per share rose 8% to $21.08.
03—Questions
Frequently Asked Questions
Why did net income jump so much from 1993 to 1994?
Most of the increase reflects the absence of 1993's $141 million after-tax cumulative effect charge from adopting SFAS 106 (postretirement benefits), SFAS 112 (postemployment benefits), and SFAS 109 (income taxes). Underlying growth was also strong: income before accounting changes rose 13% to $227 million, helped by margin gains, lower selling and administrative expense as a percentage of sales, and a $36 million gain on the disposition of a foreign investment.
What is driving the weakness in the Diagnostic Systems segment?
Growth in traditional microbiology slowed as U.S. and European cost-containment efforts changed test protocols. FACS cellular analysis sales were hurt by competition, regulatory delays for new products, and tight research budgets. European government cost containment also reduced instrumented systems volume in Italy, Spain, and Germany. Management is responding by exiting underperforming lines and refocusing on DNA probes for infectious disease and clinical cellular analysis, though it expects these pressures to continue.
How is management using excess cash?
Management repurchased 5.4 million shares for $210 million in fiscal 1994 at an average of $39.24, with 9.9 million shares still authorized under a September 1994 program. It also intends to pursue strategic acquisitions with substantial excess cash expected over the next several years. Total debt is expected to stay near the 1994 level through 1995, and the company is accelerating repatriation of cash from its Puerto Rico subsidiaries.
Are there any notable risks or one-time items affecting future earnings?
Yes. The effective tax rate was 23.3% in 1994, but management expects it to rise in 1995 as tax benefits from Puerto Rico operations decline. Brazil remains a volatility risk due to high inflation and currency devaluations, though it represents 3% or less of consolidated results. Foreign exchange losses of $11 million were recorded in 1994, and the 1994 results include a $30 million special charge and a $36 million gain on an investment sale that won't recur. The company also expects $211 million of long-term debt maturities in 1996.
Does the company have a strong liquidity position?
Yes. The current ratio improved to 2.0 from 1.8, short-term debt fell to 21% of total debt from 23%, and cash and equivalents rose to $95 million. The company had $240 million in unused confirmed U.S. short-term credit lines and $150 million in unused long-term lines, plus additional unconfirmed lines abroad. Management expressed high confidence in refinancing maturing debt.
04—Continue